InsightRP2 Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Göttingen

About this trial

InsightRP2 is a secure online patient registry specific to RP2-associated retinitis pigmentosa (RP). It is our goal to further the scientific understanding of this rare disease and to support research in to a gene therapy for RP2-associated RP.

We collect medical, genetic and imaging data from people affected by RP2-associated RP and will coduct a natural history study as well as image analysis studies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

A molecular genetic diagnosis involving a heterozygous or hemizygous variant in RP2 and a written informed consent to participate are required for access to the registry questionnaire. Patients of all ages meeting the above criteria will be allowed to participate. As documentation will be in English and German, those who can navigate these pages will be included.

Disqualifiers

Patients with evidence of non-RP2 molecular genetic diagnoses will be excluded. Collection of data and further analysis will not be possible without the consent of the patient or legal guardian. Patients who cannot navigate registry documentation in English or German will be excluded.

Trial population

Individuals affected by RP2-associated Retinitis pigmentosa worldwide.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

200 Participants
are grouped into 1 trial group
Group A: Individuals with Retinitis pigmentosa due to a variant / mutation in the RP2 gene

Trial outcomes

Primary outcomes

1

Genotype-phenotype correlation age of onset

Influence of variant type on age of onset

Time frame
1 year
2

Phenotype-genotype correlation progression

Influence of variant type on disease progression

Time frame
20 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.